All In Biotech

Drug Trial Radar · NCT06790693

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor and Letrozole in Patients With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 450 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

450

Planned (sponsor's estimate)

Start

Apr 9, 2025

Primary completion

Jan 31, 2032

Study completion Feb 1, 2032

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jan 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participants with endocrine-sensitive PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced breast cancer (ABC).

Conditions

  • Breast Cancer

Interventions

  • InavolisibDrug

    Participants will receive oral inavolisib once daily (QD).

  • PlaceboDrug

    Participants will receive oral placebo QD.

  • CDK4/6iDrug

    Participants will receive CDK4/6i on either Days 1-21 or Days 1-28 of each 28-day cycle.

  • LetrozoleDrug

    Participants will receive oral letrozole QD.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to 7 years)

Locations

242 sites in 20 countries. Site status is shown where the registry gives one.

  • City of Hope - Phoenix

    Goodyear, Arizona · Recruiting

  • The Dignity Health Cancer Institute

    Phoenix, Arizona · Recruiting

  • Disney Family Cancer Center

    Burbank, California · Recruiting

  • City of Hope - Lennar Foundation Cancer Center

    Irvine, California · Recruiting

  • Scripps Health

    La Jolla, California · Recruiting

  • City Of Hope

    Long Beach, California · Recruiting

  • Cancer and Blood Specialty Clinic

    Los Alamitos, California · Recruiting

  • Ellison Medical Institute

    Los Angeles, California · Recruiting

  • Palo Alto Medical Foundation Research Center

    Palo Alto, California · Recruiting

  • Kaiser Permanente - San Marcos

    San Marcos, California · Recruiting

  • Palo Alto Medical Foundation Research Center

    San Mateo, California · Recruiting

  • Palo Alto Medical Foundation Research Center

    Sunnyvale, California · Recruiting

  • Cancer Specialists of North Florida - Jacksonville

    Jacksonville, Florida · Recruiting

  • Tallahassee Memorial HealthCare

    Tallahassee, Florida · Recruiting

  • Moffitt Cancer Center-McKinley Campus

    Tampa, Florida · Recruiting

  • Cleveland Clinic Florida

    Weston, Florida · Recruiting

  • Northwest Georgia Oncology Centers PC - Marietta

    Marietta, Georgia · Recruiting

  • Cancer Care Specialists of Central Illinois

    O'Fallon, Illinois · Recruiting

  • Springfield Clinic

    Springfield, Illinois · Recruiting

  • Carle Cancer Center

    Urbana, Illinois · Recruiting

  • City of Hope® Cancer Center Chicago

    Zion, Illinois · Recruiting

  • Baptist Health Lexington

    Lexington, Kentucky · Recruiting

  • Baptist Health Hamburg

    Lexington, Kentucky · Recruiting

  • University of Kentucky - Markey Cancer Center

    Lexington, Kentucky · Recruiting

  • University of Louisville Hospital

    Louisville, Kentucky · Recruiting

  • Baptist Health Louisville

    Louisville, Kentucky · Recruiting

  • Velocity Clinical Research

    Annapolis, Maryland · Recruiting

  • University of Maryland

    Baltimore, Maryland · Recruiting

  • Henry Ford Health System

    Detroit, Michigan · Recruiting

  • Cancer & Hematology Centers of Western Michigan

    Grand Rapids, Michigan · Recruiting

  • University of Minnesota Medical Center

    Minneapolis, Minnesota · Recruiting

  • HCA Midwest Health

    Kansas City, Missouri · Recruiting

  • Nebraska Cancer Specialists

    Grand Island, Nebraska · Recruiting

  • Nebraska Cancer Specialists

    Omaha, Nebraska · Recruiting

  • Astera Cancer Care East Brunswick

    East Brunswick, New Jersey · Recruiting

  • Summit Medical Group

    Florham Park, New Jersey · Recruiting

  • The Blavatnik Family ? Chelsea Medical Center at Mount Sinai

    New York, New York · Recruiting

  • Mount Sinai West

    New York, New York · Recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

Showing 40 of 242 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.